

CITATION REPORT

List of articles citing

Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews.

DOI: 10.3389/fphar.2021.792877

Frontiers in Pharmacology, 2021, 12, 792877.

Source: <https://exaly.com/paper-pdf/125179909/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2	Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration. 2022 , 28, 1046-1052		0
1	Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS. 2022 , 13, 204209862211432		0